|
|
|
|
|
13.01.26 - 22:54
|
Teva′s Plans to Pivot to Growth (Bloomberg)
|
|
|
Teva Pharmaceuticals CEO Richard Francis talks about innovation and sales growth at the company with Bloomberg's Katie Greifeld in San Francisco at the annual JPMorgan Healthcare Conference. (Source: Bloomberg)...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 22:06
|
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Sales and Reaffirms 2026 Revenue Guidance (Business Wire)
|
|
|
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2025, and reaffirmed its full year 2026 revenue guidance.
Preliminary and unaudited total net sales for the fourth quarter of 2025 are expected to be approximately $143 million, a reported increase of 36% compared to the same period in 2024, consisting of approximately $86 million in U.S. Glaucoma net sales, including iDose® TR net sales of approximately $45 million, approximately $33 million in International Glaucoma net sales, and approximately $24 million in Corneal Health net sales.
Preliminary and unaudited total net sales for the full year of 2025 are expected to be approximately $507 million, a reported increase of 32% compared to the full year of 2024, consisting of appr...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
